Amivantamab added to standard drugs for untreated advanced head and neck cancer
Tests amivantamab plus standard drugs in adults with untreated advanced head and neck cancer.
Plain-language title generated from the registry record
Registry title: A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Key facts
- Where
- Avignon Cedex 9, Le Mans, Lille, Marseille, Paris, Rouen Cedex, Saint-Herblain Cedex, and Villejuif, FranceSee the 9 sites
- Phase
- Phase 3
Where in France
- Sainte Catherine Institut Du Cancer Avignon-ProvenceAvignon Cedex 9, FranceTaking people
- Clinique Victor HugoLe Mans, FranceTaking people
- Centre Oscar LambretLille, FranceTaking people
- Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
- Institut CurieParis, FranceTaking people
- Centre Henri BecquerelRouen Cedex, FranceTaking people
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranceTaking people
- Institut Gustave RoussyVillejuif, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07276399EU 2025-521917-24-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
Inclusion: Be more than or equal to (>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater); Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC that is considered incurable by local therapies: a. eligible primary tumor locations are the oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primary tumor site of nasopharynx or primary tumor of unknown location; c. Must have documented local testing results per local regulations; d. Human papillomavirus (HPV) status must be known for participants with primary tumor location in oropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH). Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative; Be treatment-naive for systemic therapy in the R/M setting; Have an ECOG performance status of 0 or 1; Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1.
Exclusion: Have an uncontrolled illness; Have untreated brain metastases or history of known presence of leptomeningeal disease; Have a history of clinically significant cardiovascular disease; Known allergies, hypersensitivity, contraindications, or intolerance to excipients of: Amivantamab, Pembrolizumab, Carboplatin, Cisplatin, 5-FU and Hyaluronidase; Inadequate organ or bone marrow function.